TY - JOUR
T1 - How does the brain change in chronic migraine? Developing disease biomarkers
AU - Pozo-Rosich, Patricia
AU - Coppola, Gianluca
AU - Pascual, Julio
AU - Schwedt, Todd J.
N1 - Funding Information:
TJS receives research support from the American Migraine Foundation, Henry Jackson Foundation, National Institutes of Health, Patient-Centered Outcomes Research Institute, US Department of Defense, and Amgen. Within the past 12 months, he has received personal compensation for serving as a consultant or advisory board member for Alder, Allergan, Amgen, Biohaven, Cipla, Click Therapeutics, Eli Lilly, Equinox, Weber & Weber, and XoC Pharmaceuticals. He holds stock options in Aural Analytics and Nocira. He serves as an Associate Editor for Headache and Cephalalgia.
Funding Information:
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: PPR has received honoraria for participation in clinical trials and contribution to advisory boards or presentations from Allergan, Almirall, Amgen, Biohaven, Chiesi, Electrocore, Eli Lilly, Medscape, Novartis, and Teva. Financial support for research projects was provided by Allergan and Novartis. Headache research is supported by la Caixa Foundation, MINECO, AGAUR, Fundacion La Marato TV3, Instituto Investigacion Carlos III, Migraine Research Foundation, Mutual Medica, and PERIS. She serves as an Associate Editor for Cephalalgia, Frontiers in Neurology (Headache Section), Editor for Revista de Neurologia, and on the Advisory Board of The Journal of Headache and Pain.
Publisher Copyright:
© International Headache Society 2020.
PY - 2021/4
Y1 - 2021/4
N2 - Background: Validated chronic migraine biomarkers could improve diagnostic, prognostic, and predictive abilities for clinicians and researchers, as well as increase knowledge on migraine pathophysiology. Objective: The objective of this narrative review is to summarise and interpret the published literature regarding the current state of development of chronic migraine biomarkers. Findings: Data from functional and structural imaging, neurophysiological, and biochemical studies have been utilised towards the development of chronic migraine biomarkers. These biomarkers could contribute to chronic migraine classification/diagnosis, prognosticating patient outcomes, predicting response to treatment, and measuring treatment responses early after initiation. Results show promise for using measures of brain structure and function, evoked potentials, and sensory neuropeptide concentrations for the development of chronic migraine biomarkers, yet further optimisation and validation are still required. Conclusions: Imaging, neurophysiological, and biochemical changes that occur with the progression from episodic to chronic migraine could be utilised for developing chronic migraine biomarkers that might assist with diagnosis, prognosticating individual patient outcomes, and predicting responses to migraine therapies. Ultimately, validated biomarkers could move us closer to being able to practice precision medicine in the field and thus improve patient care.
AB - Background: Validated chronic migraine biomarkers could improve diagnostic, prognostic, and predictive abilities for clinicians and researchers, as well as increase knowledge on migraine pathophysiology. Objective: The objective of this narrative review is to summarise and interpret the published literature regarding the current state of development of chronic migraine biomarkers. Findings: Data from functional and structural imaging, neurophysiological, and biochemical studies have been utilised towards the development of chronic migraine biomarkers. These biomarkers could contribute to chronic migraine classification/diagnosis, prognosticating patient outcomes, predicting response to treatment, and measuring treatment responses early after initiation. Results show promise for using measures of brain structure and function, evoked potentials, and sensory neuropeptide concentrations for the development of chronic migraine biomarkers, yet further optimisation and validation are still required. Conclusions: Imaging, neurophysiological, and biochemical changes that occur with the progression from episodic to chronic migraine could be utilised for developing chronic migraine biomarkers that might assist with diagnosis, prognosticating individual patient outcomes, and predicting responses to migraine therapies. Ultimately, validated biomarkers could move us closer to being able to practice precision medicine in the field and thus improve patient care.
KW - CGRP
KW - CGRP
KW - Classification
KW - chronic migraine
KW - migraine
KW - neuroimaging
KW - neurophysiology
KW - predict outcomes
UR - http://www.scopus.com/inward/record.url?scp=85097505202&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097505202&partnerID=8YFLogxK
U2 - 10.1177/0333102420974359
DO - 10.1177/0333102420974359
M3 - Review article
C2 - 33291995
AN - SCOPUS:85097505202
SN - 0333-1024
VL - 41
SP - 613
EP - 630
JO - Cephalalgia
JF - Cephalalgia
IS - 5
ER -